Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bluebird Bio (NQ: BLUE )

4.810 -0.020 (-0.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,269,272
Open 4.850
Bid (Size) 4.810 (20)
Ask (Size) 4.850 (1)
Prev. Close 4.830
Today's Range 4.560 - 4.925
52wk Range 2.520 - 8.520
Shares Outstanding 67,578,549
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
These 2 Stocks Could Be About to Soar: Are They Buys?
One thing is for certain -- both of these companies are innovators. 
Via The Motley Fool
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names
As we head into December 2023, some of the hottest investment opportunities can be found in these biotech stocks. 
Via InvestorPlace

Performance

YTD
-30.69%
-30.69%
1 Month
+45.76%
+45.76%
3 Month
+26.58%
+26.58%
6 Month
+29.30%
+29.30%
1 Year
-38.57%
-38.57%

More News

Read More
2 Biotech Stocks That Could Soar in December
Via The Motley Fool
Why FLJ Group Shares Are Trading Higher By Around 96%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Is Bluebird Bio Stock a Buy?
Via The Motley Fool
Where Will Bluebird Bio Be in 1 Year?
Via The Motley Fool
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street
Via The Motley Fool
Bluebird Bio To Rally Around 267%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Why Bluebird Bio Stock Soared 7% Higher on Tuesday
Via The Motley Fool
bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
From bluebird bio, Inc.
Via Business Wire
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
Via The Motley Fool
bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million
From bluebird bio, Inc.
Via Business Wire
bluebird bio to Host Third Quarter 2023 Financial Results Conference Call
From bluebird bio, Inc.
Via Business Wire
Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges
Via Benzinga
Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst
Via Benzinga
Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?
Via The Motley Fool
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
Via Benzinga
Are Gene Therapy Stocks The Market's Next Big Winners?
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio
Via The Motley Fool
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know
Via The Motley Fool
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point?
Via Investor's Business Daily
Exposures Product Safety
More Likely to 5x First: Bluebird Bio vs. CRISPR Therapeutics
Via The Motley Fool
2 Growth Stocks That Could Rocket 88% to 99% Higher According to Wall Street
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.